Liver Transplantation Results for Hepatocellular Carcinoma in Chile

Liver transplantation Program, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Transplantation Proceedings (Impact Factor: 0.98). 02/2010; 42(1):299-301. DOI: 10.1016/j.transproceed.2009.11.034
Source: PubMed


Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Liver transplantation is the best treatment for HCC; it improves survival, cures cirrhosis, and abolishes local recurrence. We describe the outcomes of patients with HCC who underwent liver transplantation in two liver transplantation centers in Chile.
This study is a clinical series elaborated from the liver transplantation database of Pontificia Universidad Católica and Clínica Alemana between 1993 and 2009. The survival of patients was calculated using the Kaplan-Meier survival analysis. The significant alpha level was defined as <.05.
From 250 liver transplantations performed in this period, 29 were due to HCC. At the end of the study, 25 patients (86%) were alive. The mean recurrence-free survival was 30 months (range 5 months to 8 years). The 5-year survival for patients transplanted for HCC was >80%; however, the 5-year overall survival of patients who exceeded the Milan criteria in the explants was 66%. There was no difference in overall survival between patients transplanted for HCC versus other diagnosis (P = .548).
This series confirmed that liver transplantation is a good treatment for patients with HCC within the Milan criteria.

Download full-text


Available from: Ricardo Yañez,
  • Source
    • "Although HCV infection is the most important HCC risk factor in Argentina, Mexico, and Brazil, regional differences have been described between northern and southern states in Brazil. Indeed, HBV infection is the most prevalent risk factor in northern states in Brazil, as in Peru [7] [8] [9] [10] [11] [12] [13] [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death worldwide. Globally, the most important HCC risk factors are Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV), chronic alcoholism, and dietary exposure to aflatoxins. We have described the epidemiological pattern of 202 HCC samples obtained from Colombian patients. Additionally we investigated HBV/HCV infections and TP53 mutations in 49 of these HCC cases. HBV biomarkers were detected in 58.1% of the cases; HBV genotypes F and D were characterized in three of the samples. The HCV biomarker was detected in 37% of the samples while HBV/HCV coinfection was found in 19.2%. Among TP53 mutations, 10.5% occur at the common aflatoxin mutation hotspot, codon 249. No data regarding chronic alcoholism was available from the cases. In conclusion, in this first study of HCC and biomarkers in a Colombian population, the main HCC risk factor was HBV infection.
    Hepatitis research and treatment 10/2011; 2011(1):582945. DOI:10.1155/2011/582945
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver transplantation is a well-established treatment in a subset of patients with cirrhosis and hepatocellular carcinoma. The Milan criteria (single nodule up to 5 cm, up to three nodules none larger than 3 cm, with no evidence of extrahepatic spread or macrovascular invasion) have been traditionally accepted as standard of care. However, some groups have proposed that these criteria are too restrictive, and exclude some patients from transplantation who might benefit from this procedure. Transplanting patients with tumors beyond the established criteria falls into two categories, those whose tumors are beyond the Milan criteria at presentation without the use of treatment prior to transplantation (expanded criteria), and those in whom treatment allows the Milan Criteria to be fulfilled (down-staging). Currently, however, there is no international consensus regarding these approaches in clinical practice. The purpose of this systematic review is to clarify this debate through a critical analysis of available data. Finally, some comments on predictive factors apart from morphological characteristics are also addressed.
    Journal of Hepatology 06/2011; 55(5):1137-47. DOI:10.1016/j.jhep.2011.05.012 · 11.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is the first systematic review assessing the valueof the MC as an independent prognostic factor affectingthe outcomes of LT for the treatment of HCC. A comprehensive search of the literature based on stringentselection criteria produced a list of 90 studies ofsufficient quality from 1864 references. In addition, ameta-analysis of 25 sufficiently powered studiesallowed the extraction of hazard ratios that significantlyproved the prognostic power of the MC andtheir ability to capture HCCs still retaining favorablebiological characteristics.The chosen methodology has allowed the prognosticimplications of MC to emerge with a lower grade ofevidence in comparison with pure RCTs. RCTs wereprevented for HCC by the striking differences in theposttransplant survival rates observed since theimplementation of MC and those of historicalcontrols.HCCs meeting the MC have been confirmed to be aseparate prognostic category associated with goodoutcomes after LT (a 5-year survival rate of at least70%). This has prompted the integration of the MCinto staging systems, transplant indications, and prioritizationpolicies worldwide.Although the lack of homogeneity and the presenceof noncomparative, retrospective studies hamper anyfirm conclusions, this review has translated objectiveMC data into assumptions of significant evidence:1. The MC are major determinants of the prognosisof patients undergoing LT for HCC. Patientsmeeting the MC achieve survival benefits similarto those of patients with nonmalignant diagnoses.The results of LT for patients meeting theMC should be the benchmark for any proposal ofexpanded criteria, which are associated with anincreased risk of adverse outcomes in comparisonwith conventional indications (Fig. 2).2. The MC identify a subset of patients with a significantlylower risk of tumor grades higher than2 and mVI (Fig. 3). Until more precise predictorsof prognosis using molecular techniques are validated,the MC in combination with the determinationof AFP levels remain a reliable andnoninvasive instrument for selecting patientswith less aggressive HCCs more suitable for LT.3. Locoregional treatment strategies for patientswith HCCs within the MC who are listed for LT(bridging therapies) are justified for the specificendpoint of reducing the dropout of patientsfrom the transplant waiting list. Conversely, theeffect of bridging therapies on post-LT survival isnot known.4. Arbitrary treatment plans lacking prospectivedesigns and predetermined endpoints do notfacilitate indications beyond the MC and shouldnot be recommended. Copyright
    Liver Transplantation 10/2011; 17 Suppl 2(S2):S44-57. DOI:10.1002/lt.22365 · 4.24 Impact Factor
Show more